TP53 and non-small cell lung carcinoma: revealed that in advanced NSCLC patients treated with nivolumab, with or without CTLA-4 blocker ipilimumab, or pembrolizumab, the median OS in the TP53-mutated group was 18.1 months (95% CI 6.6-not reached) vs 8.1 months (95% CI 2.2–14.5, hazard ratio [HR] = 0.48; 95% CI 0.25-0.95, P=0.04) in the TP53-wild-type group and the mPFS was significantly longer in TP53-mutated patients (4.5 months, 95% CI 2.8–18.1 versus 1.4, 95% CI 1.1–3.5; P=0.03).